Investigational drug · Phase 2
GT101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent or Metastatic Cervical Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "GT101"
First trial start
2024
Apr 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GT101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent or Metastatic Cervical Cancer
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "GT101" as an intervention, largest first.
- Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical CancerPivotal-lookingRecruiting
Grit BiotechnologyIndustry
NCT06241781 · 100 participants (planned) · Start Apr 2, 2024 · Primary completion Jan 31, 2027
Drug: GT101; Gemcitabine injection and 1 more · For: Recurrent or Metastatic Cervical Cancer
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 38 sites in all
- GT101 Injection for the Treatment of Metastatic or Recurrent Solid TumorsActive, not recruiting
Grit BiotechnologyIndustry
NCT05430373 · 31 participants (planned) · Start May 23, 2022 · Primary completion Sep 25, 2025
Drug: GT101 · For: Solid Tumors, Adult
Sites: Beijing, China; Chongqing, China; Shanghai, China · 5 sites in all
Grit BiotechnologyIndustry
NCT06077903 · 10 participants · Start Jul 5, 2021 · Primary completion Dec 30, 2025
Drug: GT101 · For: Adult
Newest research
PubMed records naming it or its code names, newest first.
- Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting.
Ma Y, Su X, Feng H · Exp Hematol Oncol 2025
- Classification of Pigeonpea (Cajanus cajan (L.) Millsp.) Genotypes for Zinc Efficiency.
Behera SK, Shukla AK, Tiwari PK, et al. · Plants (Basel) 2020
- [Immunological study of the actions of auxiliary antitumor agents--effects on lymphocyte transformation reaction and natural cytotoxicity activity in nude mice].
Fujimoto S, Ishigami H, Amemiya K, et al. · Gan To Kagaku Ryoho 1982
Also in development for Recurrent or Metastatic Cervical Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
- AdebelimabPhase 22 trials
Shanghai Hengrui Pharmaceutical Co., Ltd. · Advanced Solid Tumors, Recurrent or Metastatic Cervical Cancer
- FamitinibSHR-1020Phase 21 trial
Jiangsu HengRui Medicine Co., Ltd. · Recurrent or Metastatic Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.